VIENNALAB - Established innovations in diagnostics

Variations in the CYP2C19 gene lead to inappropriate concentrations of drugs or drug metabolites in the body, which may lead to toxicity, risk of adverse drug reactions or impaired drug efficacy. The PGX-CYP2C19 StripAssay® detects genetic variants resulting in reduced or increased activity of the cytochrome P450 isoenzyme CYP2C19.

PGX-CYP2C19 StripAssay®

  • Patients carrying CYP2C19 variants may need dosage adjustment of drugs that are metabolized by this enzyme.
  • CYP2C19 loss-of-function alleles (*2 - *8) are associated with higher rates of recurrent cardiovascular events in patients receiving clopidogrel but are associated with improved response in patients receiving proton pump inhibitors.
  • The CYP2C19*17 gain-of-function allele is likely to cause failures in drug therapies, for example in the treatment with proton pump inhibitors or antidepressants.

Product Details

PGX-CYP2C19 StripAssay® ref4-750